Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1701 vs Herceptin in HER2+ metastatic breast cancer
NCT05629949Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL1701 in HER2-positive breast cancer (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Objective Response Rate at 24 weeks. Started Apr 2020; status: completed.
02
Drugs
QL1701
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05629949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629949.